Home » Stocks » MOR

MorphoSys AG (MOR)

Stock Price: $16.18 USD -0.12 (-0.74%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $16.23 +0.05 (0.31%) Jul 23, 4:43 PM
Market Cap 2.13B
Revenue (ttm) 123.67M
Net Income (ttm) -176.57M
Shares Out 131.04M
EPS (ttm) -1.25
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $16.18
Previous Close $16.30
Change ($) -0.12
Change (%) -0.74%
Day's Open 16.29
Day's Range 16.07 - 16.33
Day's Volume 99,927
52-Week Range 15.92 - 34.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, wi...

2 days ago - Accesswire

PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a res...

1 week ago - Accesswire

Company Announces Successful Completion of Tender Offer   Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:...

Other stocks mentioned: CNST
1 week ago - Accesswire

MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitr...

3 weeks ago - Accesswire

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is base...

Other stocks mentioned: INCY
4 weeks ago - Accesswire

PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constella...

1 month ago - Accesswire

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a ...

Other stocks mentioned: INCY
1 month ago - Accesswire

Investors weren't happy about the drugmaker's wheeling and dealing.

1 month ago - The Motley Fool

Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.

1 month ago - Zacks Investment Research

NEW YORK, June 2, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. ("Co...

Other stocks mentioned: CNST
1 month ago - PRNewsWire

MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion. The transaction is expected to...

Other stocks mentioned: RPRX
1 month ago - Benzinga

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Phar...

Other stocks mentioned: CNST
1 month ago - Accesswire

PLANEGG/MUNICH, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) today announced...

Other stocks mentioned: CNST
1 month ago - Business Wire

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside...

2 months ago - Accesswire

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the upco...

2 months ago - Accesswire

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal ...

Other stocks mentioned: INCY
2 months ago - Accesswire

MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in Englis...

2 months ago - Accesswire

Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a commercial-stag...

2 months ago - Accesswire

Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.

Other stocks mentioned: INCY
3 months ago - Zacks Investment Research

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first pa...

Other stocks mentioned: INCY
3 months ago - Accesswire

PLANEGG, BAVARIA / ACCESSWIRE / March 15, 2021 / Conference call and webcast (in English) tomorrow, March 16, 2021 at 2:00pm CET (1:00pm GMT/9:00am EDT) MorphoSys AG (FSE:MOR; Prime Standard Segment; MD...

4 months ago - Accesswire

Conference Call Alert PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 9, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and...

4 months ago - Accesswire

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 2, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, p...

4 months ago - Accesswire

PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 01, 2021 / MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDA...

4 months ago - Accesswire

PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health ...

Other stocks mentioned: INCY
6 months ago - Accesswire

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in anti...

6 months ago - Accesswire

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody,...

6 months ago - Accesswire

High-Yield equity REITs have regularly underperformed. We expect that trend to continue over the next decadeREITs with high yields, low FFO multiples, and weak balance sheets have regularly underperformed.

Other stocks mentioned: KBWY, PFF, VNQ
7 months ago - Seeking Alpha

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / December 17, 2020 / MorphoSys AG: Corporate Calendar 2021 Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2021 as follows:   Publication of I...

7 months ago - Accesswire

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Other stocks mentioned: INCY
8 months ago - Zacks Investment Research

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INC...

Other stocks mentioned: INCY, XNCR
8 months ago - Business Wire

Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST

Other stocks mentioned: INCY
10 months ago - Business Wire

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

11 months ago - Seeking Alpha

Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

Other stocks mentioned: HELE, PFSI, TPL
1 year ago - Zacks Investment Research

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

Other stocks mentioned: INCY
1 year ago - Zacks Investment Research

MorphoSys AG (MPSYF) CEO Jean Kress on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.

Other stocks mentioned: INCY
1 year ago - The Motley Fool

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.

1 year ago - Zacks Investment Research

MorphoSys AG's (MOR) CEO Simon Moroney on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About MOR

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; G... [Read more...]

Industry
Biotechnology
IPO Date
Mar 9, 1999
CEO
Simon Moroney
Employees
609
Stock Exchange
NASDAQ
Ticker Symbol
MOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MorphoSys stock is "Buy." The 12-month stock price forecast is 30.55, which is an increase of 88.81% from the latest price.

Price Target
$30.55
(88.81% upside)
Analyst Consensus: Buy